celecoxib has been researched along with Microsatellite Instability in 2 studies
Microsatellite Instability: The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer." | 9.51 | Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial ( Cai, Y; Cao, W; Deng, W; Deng, Y; Dou, R; He, X; Hu, H; Hu, J; Huang, L; Huang, M; Huang, Y; Kang, L; Lan, P; Ling, J; Ling, L; Liu, H; Luo, S; Ma, T; Shen, C; Shi, L; Wang, C; Wang, H; Wu, X; Wu, Z; Xie, X; Zhang, J; Zhang, X; Zhou, J, 2022) |
| "Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer." | 5.51 | Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial ( Cai, Y; Cao, W; Deng, W; Deng, Y; Dou, R; He, X; Hu, H; Hu, J; Huang, L; Huang, M; Huang, Y; Kang, L; Lan, P; Ling, J; Ling, L; Liu, H; Luo, S; Ma, T; Shen, C; Shi, L; Wang, C; Wang, H; Wu, X; Wu, Z; Xie, X; Zhang, J; Zhang, X; Zhou, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, H | 1 |
| Kang, L | 1 |
| Zhang, J | 1 |
| Wu, Z | 1 |
| Wang, H | 2 |
| Huang, M | 1 |
| Lan, P | 1 |
| Wu, X | 1 |
| Wang, C | 1 |
| Cao, W | 1 |
| Hu, J | 1 |
| Huang, Y | 1 |
| Huang, L | 1 |
| Shi, L | 1 |
| Cai, Y | 2 |
| Shen, C | 1 |
| Ling, J | 1 |
| Xie, X | 1 |
| He, X | 1 |
| Dou, R | 1 |
| Zhou, J | 1 |
| Ma, T | 1 |
| Zhang, X | 1 |
| Luo, S | 1 |
| Deng, W | 1 |
| Ling, L | 1 |
| Liu, H | 1 |
| Deng, Y | 1 |
| Raghav, KP | 1 |
| Shetty, AV | 1 |
| Kazmi, SM | 1 |
| Zhang, N | 1 |
| Morris, J | 1 |
| Taggart, M | 1 |
| Fournier, K | 1 |
| Royal, R | 1 |
| Mansfield, P | 1 |
| Eng, C | 1 |
| Wolff, RA | 1 |
| Overman, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable Non-metastatic Colorectal Cancer Patients With Mismatch Repair-deficient or Microsatellite Instability-high[NCT03926338] | Phase 1/Phase 2 | 69 participants (Anticipated) | Interventional | 2019-05-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Microsatellite Instability
| Article | Year |
|---|---|
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cele | 2022 |
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendiceal | 2013 |